
# Bumetanide Meta-Analysis for Autism Spectrum Disorder

This project evaluates the efficacy and safety of bumetanide (BTN) in the treatment of autism spectrum disorder (ASD) using systematic review and meta-analysis techniques.

## Contents

- **Forest Plot** – Visualising effect sizes across clinical trials - ![Bumteanide_Meta_Analysis](https://github.com/user-attachments/assets/9e70d179-2930-4935-8b7a-293dc40fddb6)
  
- **Funnel Plot** – Assessing publication bias - ![Publication_Bias](https://github.com/user-attachments/assets/a5fed5db-e03e-4f45-b39b-8a659f2fcdf6)
  
- **Adverse Events Bar Chart** – Comparing incidence of side effects in BTN vs. placebo groups - ![Adverse_Event_Analysis](https://github.com/user-attachments/assets/db053d5e-e6d2-480f-9e1f-4a719795663f)


## Tools Used

- **R / RStudio**: Meta-analysis, data wrangling, visualization
- **GraphPad Prism**: Statistical analysis
- **Excel**: Data collation and formatting

## Summary of Results

- **Mean CARS Score Reduction**: -1.53 (95% CI: -2.28, -0.79), indicating modest efficacy of BTN.
- **No Publication Bias Detected**: Egger’s test, *p = 0.0921*
- **Significant Adverse Events**: Higher incidence of thirst, polyuria, and hypokalaemia in BTN groups.
